After announcing a phase 3 launch based on positive midstage results, iTeos and GSK are finally sharing the highlights from ...

A targeted immunotherapy being developed by iTeos Therapeutics and GSK, it was reported at #ESMO, delivered promising ...

Results presented at ESMO showed tumor response rates that matched the bar set by analysts for success. But they may not yet be enough to dispel doubts around TIGIT as a target.

GSK and iTeos anti-TIGIT antibody belrestotug showed efficacy in a phase 2 trial in PD-L1-positive non-small cell lung cancer (NSCLC), providing some much-needed positive news for the beleaguered ...

Teos Therapeutics' belrestotug shows promising response rates in lung cancer trials. Read more to see why I'm bullish on ITOS ...

High response rates reported by GSK and iTeos at the 2024 European Society for Medical Oncology Congress offer a ray of light ...

The company said it’s notifying study investigators of the decision and telling them patients should stop treatment, which was a fixed dose of vibostolimab, an anti-TIGIT antibody, and ...

TIGIT inhibitors have long been in a difficult race toward the finish line on the non-small cell lung cancer (NSCLC) track. At the European Society for Medical Oncology (ESMO) Congress 2024, GSK ...

Tyler Hubbard Says 'Unexpected' FGL Breakup Wasn't Initiated by Him While Brian Kelley Claims It's 'Not a Beef Thing' ...